Literature DB >> 8776260

TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients.

P S Salva1, N A Doyle, L Graham, H Eigen, C M Doerschuk.   

Abstract

The cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), and intercellular adhesion molecule-1 (ICAM-1) have important roles in regulating neutrophil migration and the inflammatory response. To determine whether the concentration of these cytokines and soluble ICAM-1 (sICAM-1) in sputum was increased in patients with cystic fibrosis during acute exacerbations, we conducted (1) a cross-sectional study of 40 patients, 22 who were clinically well and 18 with acute pulmonary exacerbations; and (2) an 11 months longitudinal study of 16 patients. Significant differences in clinical scores, pulmonary function, and sputum neutrophil density were found between the acutely ill and the well group. There was a strong linear relationship (P < 0.0005) between TNF-alpha and IL-8 concentrations in sputum, but no association between clinical status and cytokine concentrations. The concentration of sICAM-1 was lower in acutely ill compared with well patients in the cross-sectional study. Recovery of exogenous IL-8 added to sputum was complete, while recovery of TNF-alpha averaged 70%. Recovery of exogenous sICAM-1 was only 43%, and the recoveries were lower in sputum samples from acutely ill patients than those from stable patients (P = 0.018). These data indicate that in cystic fibrosis patients, sputum concentrations of TNF-alpha and IL-8 are not increased during acute exacerbations of pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776260     DOI: 10.1002/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  19 in total

1.  Proinflammatory mediators disrupt glucose homeostasis in airway surface liquid.

Authors:  James P Garnett; Trang T Nguyen; James D Moffatt; Elizabeth R Pelham; Kameljit K Kalsi; Emma H Baker; Deborah L Baines
Journal:  J Immunol       Date:  2012-05-23       Impact factor: 5.422

Review 2.  Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Authors:  Maaike Cockx; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

3.  Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.

Authors:  I M Balfour-Lynn; N J Klein; R Dinwiddie
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

4.  Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis.

Authors:  N R Henig; M R Tonelli; M V Pier; J L Burns; M L Aitken
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

Review 5.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 6.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 7.  Cytokine regulation of tight junctions.

Authors:  Christopher T Capaldo; Asma Nusrat
Journal:  Biochim Biophys Acta       Date:  2008-10-08

8.  Microarray analysis reveals induction of lipoprotein genes in mucoid Pseudomonas aeruginosa: implications for inflammation in cystic fibrosis.

Authors:  Aaron M Firoved; Wojciech Ornatowski; Vojo Deretic
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Regulation of airway tight junctions by proinflammatory cytokines.

Authors:  Carolyn B Coyne; Miriam K Vanhook; Todd M Gambling; Johnny L Carson; Richard C Boucher; Larry G Johnson
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

10.  Inhibition of NFkappaB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation.

Authors:  Rangan Maitra; Melissa A Porter; Shan Huang; Brian P Gilmour
Journal:  J Inflamm (Lond)       Date:  2009-05-13       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.